Protocol for Radiofrequency Ablation of Pulmonary Neoplasms
NCT ID: NCT00232128
Last Updated: 2007-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
INTERVENTIONAL
2003-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
NCT00024076
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
NCT00109876
Outcome of Patients With Lung Masses Who Are Treated With Radiofrequency Ablation (RFA)
NCT00641238
Radiofrequency Ablation and External-Beam Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT00499447
Radiofrequency Ablation During Surgery in Treating Patients With Non-Small Cell Lung Cancer
NCT00039507
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Radiofrequency Ablation of pulmonary neoplasms
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. may benefit from multiple modalities of therapy
3. chemotherapeutic or radiation oncologic options have been exhausted
Exclusion Criteria
19 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oncology Specialties, Alabama
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marshall T. Schreeder, M.D.
Role: PRINCIPAL_INVESTIGATOR
Comprehensive Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Comprehensive Cancer Institute
Huntsville, Alabama, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCI LUN 02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.